1Giatromanolaki A. Prognostic role of angiogenesis in non-small cell lung cancer. Anticancer Res, 2001, 21(6B): 4373-4782.
2Brattstorm D, Bergqvist M, Hesselius P, et al. Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sample before, during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer, 2004, 43(1): 55-62.
3Sandler AB, Gray R, Brahmer J, et al. Randomized phase Ⅱ/Ⅲ Trial of pacitaxel plus carboplatin with or without bevacizubmab in patients with advanced non-squamous non-small cell lung cancer: An Easten Cooperative Oncology Group (ECOG) trial-E4599. J Clin Oncol, 2005, 23(16suppl): 2s.
4Brock CS, Lee SM. Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. Eur Respir J, 2002, 19(3): 557-570.
5Willett GG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 2004, 10(2): 145-147.
6Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol, 2005, 23(16suppl): 1 s.
7Eskens FA. Angiogenesis inhibitors in clinical development: where are we now and where are we going? Br J Cancer, 2004, 90(1): 1-7.
8Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol,2003, 21(1): 60-65.
9Hurwitz H, Fehrenbacher L, Novotny W, ct al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004, 350(23): 2335-2342.
10Kathy M, Molin W, Julie G, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 2007, 357(26): 2666-2676.
3Seike M,Gemma A. Therapeutic biomarkers of EGFR-TKI[J].{H}Gan To Kagaku Ryoho,2012,(11):1613-1617.
4Peuvrel L,Bachmeyer C,Reguiai Z. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors[J].{H}SUPPORTIVE CARE IN CANCER,2012,(05):909-921.
5McLellan B,Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib[J].{H}DERMATOLOGIC THERAPY,2011,(04):396-400.
6Di Cosimo S. Heart to heart with trastuzumab:a review on cardiac toxicity[J].Target Oncol,2011,(04):189-195.
7Shord SS,Bressler LR,Tierney LA. Understanding and managing the possible adverse effects associated with bevacizumab[J].{H}American Journal of Health System Pharmacy,2009,(11):999-1013.
8Gupta R,Maitland ML. Sunitinib,hypertension,and heart failure:a model for kinase inhibitor-mediated cardiotoxic-ity[J].{H}Current Hypertension Reports,2011,(06):430-435.
9Fukuoka M,Yano S,Giaccone G. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL1 Trial)[J].{H}Journal of Clinical Oncology,2003,(12):2237-2246.
10Fidler MJ,Argiris A,Patel JD. The potential predic-tive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and cele-coxib[J].{H}Clinical Cancer Research,2008,(07):2088-2094.
